Arginine Metabolism: A Potential Target in Pancreatic Cancer Therapy

0
0
0

Arginine Metabolism: A Potential Target in Pancreatic Cancer Therapy

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, remains one of the deadliest malignancies, with a 5-year survival rate below 9% in the United States. Its aggressive nature, late diagnosis, and resistance to conventional therapies like chemotherapy, radiation, and immunotherapy necessitate novel therapeutic strategies. Emerging research highlights metabolic reprogramming as a hallmark of cancer, with arginine metabolism emerging as a critical regulator of PDAC progression and a promising therapeutic target. This review explores the role of arginine metabolism in PDAC biology, evaluates the efficacy of arginine deprivation therapies, and discusses mechanisms of resistance and immune modulation.

Arginine Synthesis, Degradation, and Metabolic Pathways

Arginine, a semi-essential amino acid, is synthesized endogenously via the urea cycle in the liver and kidneys. The rate-limiting enzyme argininosuccinate synthetase 1 (ASS1) converts citrulline to argininosuccinate, which is further processed into arginine by argininosuccinate lyase (ASL). However, pancreatic cancer cells frequently exhibit ASS1 deficiency, rendering them auxotrophic for extracellular arginine. This deficiency arises from promoter hypermethylation or transcriptional suppression by oncogenic pathways involving c-Myc and hypoxia-inducing factor-1α (HIF-1α).

Arginine is degraded by four key enzymes:

  1. Arginase (ARG1/ARG2): Converts arginine to ornithine and urea, feeding into polyamine synthesis.
  2. Nitric oxide synthase (NOS): Generates nitric oxide (NO) and citrulline. NOS isoforms (inducible NOS/iNOS, endothelial NOS/eNOS) are overexpressed in PDAC and linked to angiogenesis and invasion.
  3. Arginine decarboxylase (ADC): Produces agmatine, a precursor for polyamines.
  4. Glycine amidinotransferase (GATM): Initiates creatine synthesis.

PDAC cells compensate for ASS1 loss by upregulating arginine transporters (SLC7A2, SLC3A2) and utilizing macropinocytosis to scavenge extracellular proteins. The tumor microenvironment (TME) further modulates arginine availability; cancer-associated fibroblasts (CAFs) expressing ARG2 contribute to arginine catabolism, while myeloid-derived suppressor cells (MDSCs) secrete ARG1 to suppress T-cell immunity.

Arginine Metabolism in PDAC Progression

1. Cell Proliferation and Survival

Arginine deprivation via pegylated arginine deiminase (ADI-PEG20) or arginase (PEG-rhArg) induces autophagic cell death in ASS1-deficient PDAC cells (e.g., Panc-1, MiaPaca-2). Surviving cells exhibit S-phase arrest due to nucleotide depletion from upregulated asparagine synthetase (ASNS). In contrast, ASS1-expressing cells (e.g., BxPC3) remain resistant but display sensitization to gemcitabine and radiation when combined with arginine deprivation.

2. Invasion and Metastasis

Arginine regulates epithelial-mesenchymal transition (EMT) markers (Snail, Slug, Twist) and matrix metalloproteinases (MMP1/9). NO derived from arginine activates RhoA and PI3K/AKT signaling, promoting PDAC cell motility. Elevated iNOS in PDAC correlates with advanced tumor stage and poor prognosis.

3. Metabolic Crosstalk

Arginine metabolism intersects with glutamine and glucose pathways. Glutamine deprivation upregulates p53-dependent SLC7A3, enhancing arginine uptake and mTORC1 activation. PDAC cells under arginine starvation reprogram glucose flux into serine/glycine synthesis (via phosphoglycerate dehydrogenase/PHGDH) and increase glutamine anaplerosis, creating metabolic vulnerabilities exploitable by combination therapies.

Arginine Deprivation Therapy: Mechanisms and Clinical Applications

1. Enzyme-Based Deprivation Strategies

  • ADI-PEG20: A microbial enzyme that converts arginine to citrulline. Phase I/II trials in PDAC showed a 45.5% overall response rate when combined with gemcitabine/nab-paclitaxel, extending median progression-free survival to 6.1 months.
  • PEG-rhArg: Depletes arginine via hydrolysis. In hepatocellular carcinoma, high-dose PEG-rhArg extended progression-free survival to 6.4 months in responders.

2. Synergy with Conventional Therapies

  • Chemotherapy: Arginine deprivation upregulates deoxycytidine kinase (dCK) and downregulates ribonucleotide reductase (RRM1), enhancing gemcitabine efficacy.
  • Radiation: ADI-PEG20 potentiates radiation-induced endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) in ASS1-deficient cells.
  • HDAC Inhibitors: Panobinostat synergizes with ADI-PEG20 by destabilizing DNA repair proteins (CtIP), causing synthetic lethality in ASS1-low PDAC.

Mechanisms of Resistance to Arginine Deprivation

1. ASS1 Re-expression

Long-term ADI-PEG20 treatment selects for PDAC clones with restored ASS1 expression via promoter demethylation or c-Myc stabilization. These cells regain arginine autonomy but exhibit metabolic dependencies on polyamines, which can be targeted with ornithine decarboxylase inhibitors (e.g., difluoromethylornithine/DFMO).

2. Metabolic Adaptation

Resistant cells shift toward glycolysis (increased LDHA, GLUT1) and glutamine oxidation. Co-targeting PHGDH (serine synthesis) or glutaminase (GLS) with arginine deprivation induces synthetic lethality.

3. Immunogenicity and Microenvironment

Anti-drug antibodies against ADI-PEG20 develop in 30–40% of patients, reducing efficacy. CAFs expressing ARG2 sustain arginine catabolism in hypoxic niches, while MDSCs secrete ARG1 to inhibit T-cell proliferation.

Arginine Metabolism in Immunotherapy

1. Immune Suppression via MDSCs

Granulocytic MDSCs (CD11b+Gr1+Ly6C−) in PDAC TME express ARG1 and iNOS, depleting arginine and producing NO to paralyze T cells. CD13high neutrophil-like MDSCs correlate with perineural invasion and poor survival.

2. Checkpoint Inhibitor Combinations

Preclinical studies show ARG inhibition (e.g., CB-1158) reverses T-cell exhaustion and enhances anti-PD-1 responses. In melanoma, arginine depletion with BCT-100 (pegylated arginase) achieved complete remission in pembrolizumab-resistant cases.

3. CAR-T Cell Challenges

Dense PDAC stroma and immunosuppressive metabolites (e.g., polyamines, NO) limit CAR-T efficacy. Strategies to degrade stromal barriers (e.g., PEGPH20) or co-administer arginase inhibitors are under investigation.

Conclusion

Arginine metabolism represents a linchpin in PDAC biology, influencing tumor growth, metastasis, and immune evasion. ASS1 deficiency, while a vulnerability, triggers adaptive resistance mechanisms that necessitate combination therapies targeting parallel metabolic pathways (polyamines, glutamine) or immune checkpoints. Clinical trials underscore the potential of enzyme-based arginine depletion, particularly in biomarker-selected patients with ASS1-low tumors. Future research must address the dynamic interplay between cancer cells, stromal elements, and immune cells to optimize therapeutic outcomes.

DOI: doi.org/10.1097/CM9.0000000000001216

Was this helpful?

0 / 0